Discover and read the best of Twitter Threads about #keytruda
Most recents (9)
$NWBO #DCVaxL
The #PolyICLC adjuvant has already been approved for adjuvant use in other cancers. Under new FDA rules, real world data and validation of the results already seen may make it very easy not only to expand the label and access to #Hiltonol, but also ease insurance / Medicare if
If #DCVaxL is approved. It should be straightforward to add #PolyICLC $NWBO.
See, “Poly ICLC (Hiltonol®): an immune adjuvant targeting the Toll-like receptor 3 (TLR3) pathway; approved for subsets of patients with squamous cell carcinoma”
cancerresearch.org/treatment-type…
See, “Poly ICLC (Hiltonol®): an immune adjuvant targeting the Toll-like receptor 3 (TLR3) pathway; approved for subsets of patients with squamous cell carcinoma”
cancerresearch.org/treatment-type…
$PVCT-related medical journal article: DePalo DK, Zager JS. Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress. Cancers. 2023; 15(5):1404. doi.org/10.3390/cancer…. @MoffittNews @USFHealthMed. Intralesional agent PV-10… twitter.com/i/web/status/1… 
Other $PVCT work by Dr. Zager (and Moffitt Cancer Center) as a principal investigator for us: PV-10 (#RoseBengalSodium) + #Keytruda (#pembrolizumab) for immune checkpoint blockade-naïve Stage III cutaneous melanoma
Other $PVCT work by Dr. Zager (and Moffitt Cancer Center) as a principal investigator for us: PV-10 (#RoseBengalSodium) + #Keytruda (#pembrolizumab) for immune checkpoint blockade-refractory advanced melanoma
1/ $PVCT’s PV-10 (#RoseBengalSodium) Immuno-Oncology Cycle & PD-1-Combination Mechanism. A #THREAD. #InduceAndBoost.
2/ Over the past decade-plus, cancer immunotherapy with antibodies targeting the PD-1 immune checkpoint pathway (i.e., PD-1 inhibitors #PD1) has yielded dramatic improvement in clinical outcome for many patients with #CutaneousMelanoma. #Keytruda #Opdivo #otherPD1s #PDL1s
3/ However, patients with Stage III disease and, in particular, those with in-transit disease (i.e., in-transit melanoma; ITM #IntransitMelanoma), have presented unique challenges with regard to response rate and durability of response.
$PVCT Releases 2023 Stockholder Letter globenewswire.com/news-release/2… #rosebengal #rosebengalsodium
1/ $PVCT 2023 Shareholder Letter: (2) Design, prepare, and potentially commence a Phase 2/3 RCT of PV-10®+SOC checkpoint vs monotherapy SOC checkpoint ($MRK #keytruda, $BMY #opdivo) for 1st-line Stage III cutaneous melanoma. #rosebengal #rosebengalsodium. A THREAD.
2/ Utilizing clinical data from an ongoing, multi-cohort, Phase 1b/2 study of PV-10+checkpoint ($MRK #keytruda) for checkpoint-naïve metastatic melanoma (NCT02557321). #rosebengal #rosebengalsodium.
Exploring Adjuvants with #DCVaxL: POLY ICLC TLR 3 Agonist adjuvant discussion, #DrLindaLiau, early trial P 1. Using adjuvants w/ #DCVaxL $NWBO #Murcidencel #DCVax
Survival Data w/Adjuvants, small early trial:
Survival Data w/Adjuvants, small early trial:
Fuller Discussion re early trial with #DCVaxL + adjuvants, including Poly ICLC:
Re single agent checkpoint inhibitors, without DCVaxL, in Glioblastoma:
Dendritic Cell Vaccine for Patients With Brain Tumors - Full Text View - ClinicalTrials.gov
#AdjuvantStimulus #PolyICLC
Ongoing #DCVaxL trial with Adjuvant stimulus, will likely further improve outcomes with #DCVaxL $NWBO clinicaltrials.gov/ct2/show/NCT01…
#AdjuvantStimulus #PolyICLC
Ongoing #DCVaxL trial with Adjuvant stimulus, will likely further improve outcomes with #DCVaxL $NWBO clinicaltrials.gov/ct2/show/NCT01…
$NWBO DEDUCED RECKONING: Northwest Bio reports Phase 3 results.
#DCVaxL
@joanlappin
finance.yahoo.com/news/deduced-r…
#DCVaxL
@joanlappin
finance.yahoo.com/news/deduced-r…
1/ "Only 5% of glio patients survive for five years. So how stunning is it for DCVAX-L to see life expectancy at 60 months rise from 5.7% to 13%, an increase of 228%. Some patients have seen total remission glio and are cancer free more than a decade after treatment.
2/ For example, Brad Silver participated in the Phase 1 trial 17 years ago and is cancer free now."
1/ Re $NWBO and #DCVaxL aka "ATL-DC" in brief:
#DrLindaLiau, principal investigator for a Phase 3 #DCVaxL trial recently gave a lecture covering the #DCVaxLComboTrial with #Keytruda.
#DrLindaLiau, principal investigator for a Phase 3 #DCVaxL trial recently gave a lecture covering the #DCVaxLComboTrial with #Keytruda.
2/ $NWBO and UCLA have a patent application pending approval for immunotherapy combinations with #DCVaxL.
3/ The #DCVaxLComboTrial appears to be intended to further the patent process and also to likely advance new commercial opportunities, including potential partnerships, for $NWBO. Many commentators have suggested some obvious potential partners.
$LOAC - SPAC for 4D Pharma (#DDDD) due diligence thread including:
✅Company overview
✅Product overview
✅Collaborations with major #pharma companies ( $MRK, $PFE, and Merck KGaA)
✅Key competitors
✅Pipeline and upcoming catalysts
✅Company overview
✅Product overview
✅Collaborations with major #pharma companies ( $MRK, $PFE, and Merck KGaA)
✅Key competitors
✅Pipeline and upcoming catalysts
𝘾𝙤𝙢𝙥𝙖𝙣𝙮 𝙤𝙫𝙚𝙧𝙫𝙞𝙚𝙬
4D Pharma (#DDDD) is a pharmaceutical company leading the development of a novel class of drugs derived from the microbiome (LBPs).🦠
Here is a quick overview of how 4D utilizes the microbiome for unique solutions. vimeo.com/249654919
4D Pharma (#DDDD) is a pharmaceutical company leading the development of a novel class of drugs derived from the microbiome (LBPs).🦠
Here is a quick overview of how 4D utilizes the microbiome for unique solutions. vimeo.com/249654919
#DDDD / $LOAC is leading the microbiome sector with:
✅More than 1,000 granted patents
✅Partnerships with several large biopharma companies (Merck, Pfizer, Merck KGaA) and in talks with others
✅Unique discovery platform of live biotherapeutic products (LBPs)
✅More than 1,000 granted patents
✅Partnerships with several large biopharma companies (Merck, Pfizer, Merck KGaA) and in talks with others
✅Unique discovery platform of live biotherapeutic products (LBPs)
